Exane Derivatives Sol Gel Technologies Ltd. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Sol Gel Technologies Ltd. stock. As of the latest transaction made, Exane Derivatives holds 61 shares of SLGL stock, worth $35. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61
Previous 61
-0.0%
Holding current value
$35
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SLGL
# of Institutions
21Shares Held
5.31MCall Options Held
12.8KPut Options Held
0-
Phoenix Holdings Ltd. Givatayim, L32.47MShares$1.43 Million0.03% of portfolio
-
Migdal Insurance & Financial Holdings Ltd.1.23MShares$711,9770.02% of portfolio
-
Harel Insurance Investments & Financial Services Ltd.920KShares$533,7930.01% of portfolio
-
Yelin Lapidot Holdings Management Ltd. Tel Aviv, L3227KShares$131,7050.04% of portfolio
-
Raymond James Financial Inc St. Petersburg, FL109KShares$63,2140.0% of portfolio
About Sol-Gel Technologies Ltd.
- Ticker SLGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,129,500
- Market Cap $13.4M
- Description
- Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has compl...